Thurston Springer Miller Herd & Titak Inc. decreased its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 4.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,231 shares of the company’s stock after selling 249 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Zoetis were worth $1,022,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of ZTS. Vanguard Group Inc. increased its holdings in Zoetis by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after purchasing an additional 414,605 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Zoetis by 4.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after buying an additional 178,303 shares during the last quarter. Capital Research Global Investors grew its position in shares of Zoetis by 2.3% during the first quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock worth $685,416,000 after buying an additional 90,330 shares in the last quarter. Clearbridge Investments LLC increased its stake in shares of Zoetis by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock worth $527,774,000 after buying an additional 166,517 shares during the last quarter. Finally, Sarasin & Partners LLP raised its holdings in Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after acquiring an additional 1,904,899 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts have weighed in on ZTS shares. JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday. Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Piper Sandler boosted their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, BTIG Research increased their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $221.44.
Zoetis Stock Performance
ZTS opened at $190.08 on Monday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The business’s 50 day moving average is $188.07 and its 200-day moving average is $176.25. The stock has a market cap of $86.73 billion, a PE ratio of 36.62, a price-to-earnings-growth ratio of 2.95 and a beta of 0.89. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.
Zoetis (NYSE:ZTS – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period last year, the firm earned $1.41 EPS. The firm’s revenue was up 8.3% compared to the same quarter last year. On average, analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current year.
Zoetis Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.91%. Zoetis’s dividend payout ratio is presently 33.14%.
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Recommended Stories
- Five stocks we like better than Zoetis
- The Basics of Support and Resistance
- 3 Stocks Under $20 for Buy-and-Hold Investors Seeking Growth
- Golden Cross Stocks: Pattern, Examples and Charts
- BlackRock’s Earnings Reveal Market Shift: Why Bonds Are in Favor
- What is the Nikkei 225 index?
- JPMorgan Can Hit New Highs This Year: Here’s Why
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.